Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated Through Distinct Kinase and Interferon Signaling Networks
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
Relative Selectivity of Plant Cardenolides for Na+/K+-Atpases from the Monarch Butterfly and Non-Resistant Insects
fpls-09-01424 September 26, 2018 Time: 15:23 # 1 ORIGINAL RESEARCH published: 28 September 2018 doi: 10.3389/fpls.2018.01424 Relative Selectivity of Plant Cardenolides for NaC/KC-ATPases From the Monarch Butterfly and Non-resistant Insects Georg Petschenka1*, Colleen S. Fei2, Juan J. Araya3, Susanne Schröder4, Barbara N. Timmermann5 and Anurag A. Agrawal2 1 Institute for Insect Biotechnology, Justus-Liebig-Universität, Giessen, Germany, 2 Department of Ecology and Evolutionary Biology, Cornell University, Ithaca, NY, United States, 3 Centro de Investigaciones en Productos Naturales, Escuela de Química, Instituto de Investigaciones Farmacéuticas, Facultad de Farmacia, Universidad de Costa Rica, San Pedro, Costa Rica, 4 Institut für Medizinische Biochemie und Molekularbiologie, Universität Rostock, Rostock, Germany, 5 Department of Medicinal Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, United States A major prediction of coevolutionary theory is that plants may target particular herbivores with secondary compounds that are selectively defensive. The highly specialized Edited by: monarch butterfly (Danaus plexippus) copes well with cardiac glycosides (inhibitors Daniel Giddings Vassão, C C Max-Planck-Institut für chemische of animal Na /K -ATPases) from its milkweed host plants, but selective inhibition Ökologie, Germany of its NaC/KC-ATPase by different compounds has not been previously tested. Reviewed by: We applied 17 cardiac glycosides to the D. plexippus-NaC/KC-ATPase and to the Stephen Baillie Malcolm, C C Western Michigan University, more susceptible Na /K -ATPases of two non-adapted insects (Euploea core and United States Schistocerca gregaria). Structural features (e.g., sugar residues) predicted in vitro Supaart Sirikantaramas, inhibitory activity and comparison of insect NaC/KC-ATPases revealed that the monarch Chulalongkorn University, Thailand has evolved a highly resistant enzyme overall. -
Eiichi Kimura, MD, Department of Internal Medicine, Nippon Medical
Effect of Metildigoxin (ƒÀ-Methyldigoxin) on Congestive Heart Failure as Evaluated by Multiclinical Double Blind Study Eiichi Kimura,* M.D. and Akira SAKUMA,** Ph.D. In Collaboration with Mitsuo Miyahara, M.D. (Sapporo Medi- cal School, Sapporo), Tomohiro Kanazawa, M.D. (Akita Uni- versity School of Medicine, Akita), Masato Hayashi, M.D. (Hiraga General Hospital, Akita), Hirokazu Niitani, M.D. (Showa Uni- versity School of Medicine, Tokyo), Yoshitsugu Nohara, M.D. (Tokyo Medical College, Tokyo), Satoru Murao, M.D. (Faculty of Medicine, University of Tokyo, Tokyo), Kiyoshi Seki, M.D. (Toho University School of Medicine, Tokyo), Michita Kishimoto, M.D. (National Medical Center Hospital, Tokyo), Tsuneaki Sugi- moto, M.D. (Faculty of Medicine, Kanazawa University, Kana- zawa), Masao Takayasu, M.D. (National Kyoto Hospital, Kyoto), Hiroshi Saimyoji, M.D. (Faculty of Medicine, Kyoto University, Kyoto), Yasuharu Nimura, M.D. (Medical School, Osaka Uni- versity, Osaka), Tatsuya Tomomatsu, M.D. (Kobe University, School of Medicine, Kobe), and Junichi Mise, M.D. (Yamaguchi University, School of Medicine, Ube). SUMMARY The efficacy on congestive heart failure of metildigoxin (ƒÀ-methyl- digoxin, MD), a derivative of digoxin (DX), which had a good absorp- tion rate from digestive tract, was examined in a double blind study using a group comparison method. After achieving digitalization with oral MD or intravenous deslanoside in the non-blind manner, mainte- nance treatment was initiated and the effects of orally administered MD and DX were compared. MD was administered in 44 cases , DX in 42. The usefulness of the drug was evaluated after 2 weeks , taking into account the condition of the patient and the ease of administration . -
Cardenolide Biosynthesis in Foxglove1
Review 491 Cardenolide Biosynthesis in Foxglove1 W. Kreis2,k A. Hensel2, and U. Stuhlemmer2 1 Dedicated to Prof. Dr. Dieter He@ on the occasion of his 65th birthday 2 Friedrich-Alexander-Universität Erlangen, Institut für Botanik und Pharmazeutische Biologie, Erlangen, Germany Received: January 28, 1998; Accepted: March 28, 1998 Abstract: The article reviews the state of knowledge on the genuine cardiac glycosides present in Digitalis species have a biosynthesis of cardenolides in the genus Digitalis. It sum- terminal glucose: these cardenolides have been termed marizes studies with labelled and unlabelled precursors leading primary glycosides. After harvest or during the controlled to the formulation of the putative cardenolide pathway. Alter- fermentation of dried Digitalis leaves most of the primary native pathways of cardenolide biosynthesis are discussed as glycosides are hydrolyzed to yield the so-called secondary well. Special emphasis is laid on enzymes involved in either glycosides. Digitalis cardenolides are valuable drugs in the pregnane metabolism or the modification of cardenolides. medication of patients suffering from cardiac insufficiency. In About 20 enzymes which are probably involved in cardenolide therapy genuine glycosides, such as the lanatosides, are used formation have been described "downstream" of cholesterol, as well as compounds obtained after enzymatic hydrolysis including various reductases, oxido-reductases, glycosyl trans- and chemical saponification, for example digitoxin (31) and ferases and glycosidases as well as acyl transferases, acyl es- digoxin, or chemical modification of digoxin, such as metildig- terases and P450 enzymes. Evidence is accumulating that car- oxin. Digitalis lanata Ehrh. and D.purpurea L are the major denolides are not assembled on one straight conveyor belt but sources of the cardiac glycosides most frequently employed in instead are formed via a complex multidimensional metabolic medicine. -
Quo Vadis Cardiac Glycoside Research?
toxins Review Quo vadis Cardiac Glycoside Research? Jiˇrí Bejˇcek 1, Michal Jurášek 2 , VojtˇechSpiwok 1 and Silvie Rimpelová 1,* 1 Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, Prague 6, Czech Republic; [email protected] (J.B.); [email protected] (V.S.) 2 Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 3, Prague 6, Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +420-220-444-360 Abstract: AbstractCardiac glycosides (CGs), toxins well-known for numerous human and cattle poisoning, are natural compounds, the biosynthesis of which occurs in various plants and animals as a self-protective mechanism to prevent grazing and predation. Interestingly, some insect species can take advantage of the CG’s toxicity and by absorbing them, they are also protected from predation. The mechanism of action of CG’s toxicity is inhibition of Na+/K+-ATPase (the sodium-potassium pump, NKA), which disrupts the ionic homeostasis leading to elevated Ca2+ concentration resulting in cell death. Thus, NKA serves as a molecular target for CGs (although it is not the only one) and even though CGs are toxic for humans and some animals, they can also be used as remedies for various diseases, such as cardiovascular ones, and possibly cancer. Although the anticancer mechanism of CGs has not been fully elucidated, yet, it is thought to be connected with the second role of NKA being a receptor that can induce several cell signaling cascades and even serve as a growth factor and, thus, inhibit cancer cell proliferation at low nontoxic concentrations. -
Oleandrin: a Cardiac Glycosides with Potent Cytotoxicity
PHCOG REV. REVIEW ARTICLE Oleandrin: A cardiac glycosides with potent cytotoxicity Arvind Kumar, Tanmoy De, Amrita Mishra, Arun K. Mishra Department of Pharmaceutical Chemistry, Central Facility of Instrumentation, School of Pharmaceutical Sciences, IFTM University, Lodhipur, Rajput, Moradabad, Uttar Pradesh, India Submitted: 19-05-2013 Revised: 29-05-2013 Published: **-**-**** ABSTRACT Cardiac glycosides are used in the treatment of congestive heart failure and arrhythmia. Current trend shows use of some cardiac glycosides in the treatment of proliferative diseases, which includes cancer. Nerium oleander L. is an important Chinese folk medicine having well proven cardio protective and cytotoxic effect. Oleandrin (a toxic cardiac glycoside of N. oleander L.) inhibits the activity of nuclear factor kappa‑light‑chain‑enhancer of activated B chain (NF‑κB) in various cultured cell lines (U937, CaOV3, human epithelial cells and T cells) as well as it induces programmed cell death in PC3 cell line culture. The mechanism of action includes improved cellular export of fibroblast growth factor‑2, induction of apoptosis through Fas gene expression in tumor cells, formation of superoxide radicals that cause tumor cell injury through mitochondrial disruption, inhibition of interleukin‑8 that mediates tumorigenesis and induction of tumor cell autophagy. The present review focuses the applicability of oleandrin in cancer treatment and concerned future perspective in the area. Key words: Cardiac glycosides, cytotoxicity, oleandrin INTRODUCTION the toad genus Bufo that contains bufadienolide glycosides, the suffix-adien‑that refers to the two double bonds in the Cardiac glycosides are used in the treatment of congestive lactone ring and the ending-olide that denotes the lactone heart failure (CHF) and cardiac arrhythmia. -
(12) Patent Application Publication (10) Pub. No.: US 2012/0264810 A1 Lin Et Al
US 20120264810A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0264810 A1 Lin et al. (43) Pub. Date: Oct. 18, 2012 (54) COMPOSITIONS AND METHODS FOR 61/400,763, filed on Jul. 30, 2010, provisional appli ENHANCING CELLULARUPTAKE AND cation No. 61/400,758, filed on Jul. 30, 2010. INTRACELLULAR DELVERY OF LIPID PARTICLES Publication Classification (75) Inventors: Paulo J.C. Lin, Vancouver (CA); (51) Int. Cl. Yuen Yic. Tam, Vancouver (CA); C07. 4I/00 (2006.01) Srinivasulu Masuna, Edmonton A6II 47/24 (2006.01) (CA); Marco A. Ciufolini, CI2N 5/071 (2010.01) Vancouver (CA); Michel Roberge, A63L/73 (2006.01) Vancouver (CA); Pieter R. Cullis, A6II 47/22 (2006.01) Vancouver (CA) C07D 215/46 (2006.01) A 6LX 3L/705 (2006.01) (73) Assignee: The University of British (52) U.S. Cl. ............ 514/44A: 540/5: 546/163; 514/788: Columbia, Vancouver (CA) 514/44 R; 435/375 (21) Appl. No.: 13/497,395 (57) ABSTRACT (22) PCT Filed: Sep. 22, 2010 Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are describedIn particu (86). PCT No.: PCT/B2O1O/OO2518 lar embodiments, the methods of the invention include con tacting a cell with a lipid particle and a compound that binds S371 (c)(1), a Na+/K+ ATPase to enhance uptake of the lipid particle b\the (2), (4) Date: Jul. 3, 2012 cell Related compositions useful in practicing methods include lipid particles comprising a conjugated compound Related U.S. Application Data that enhances uptake of the lipid particles b\ the cell The (60) Provisional application No. -
Wo 2008/127291 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US). -
Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides
Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 794930, 9 pages http://dx.doi.org/10.1155/2014/794930 Review Article Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides José Manuel Calderón-Montaño,1 Estefanía Burgos-Morón,1 Manuel Luis Orta,2 Dolores Maldonado-Navas,1 Irene García-Domínguez,1 and Miguel López-Lázaro1 1 Department of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain 2 DepartmentofCellBiology,FacultyofBiology,UniversityofSeville,Spain Correspondence should be addressed to Miguel Lopez-L´ azaro;´ [email protected] Received 27 February 2014; Revised 25 April 2014; Accepted 28 April 2014; Published 8 May 2014 Academic Editor: Gautam Sethi Copyright © 2014 Jose´ Manuel Calderon-Monta´ no˜ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cardiac glycosides, also known as cardiotonic steroids, are a group of natural products that share a steroid-like structure with an + + unsaturated lactone ring and the ability to induce cardiotonic effects mediated by a selective inhibition of the Na /K -ATPase. Cardiac glycosides have been used for many years in the treatment of cardiac congestion and some types of cardiac arrhythmias. Recent data suggest that cardiac glycosides may also be useful in the treatment of cancer. These compounds typically inhibit cancer cell proliferation at nanomolar concentrations, and recent high-throughput screenings of drug libraries have therefore identified cardiac glycosides as potent inhibitors of cancer cell growth. Cardiac glycosides can also block tumor growth in rodent models, which further supports the idea that they have potential for cancer therapy. -
AACR2007-5554P
High Throughput screening for modulators of tissue-kallikrein expression Ioannis Prassas, Miltiadis Paliouras and Eleftherios P. Diamandis 1 The Samuel Lunenfeld Research Institute Department of Laboratory Medicine and Pathobiology, University of Toronto 2Samuel Lunenfeld Research Institute, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada ABSTRACT METHODS RESULTS Human tissue kallikreins (KLKs) comprise a subgroup of 15 homologous secreted serine proteases. A) Initial screening Primarily known for their clinical use as cancer biomarkers (e.g. PSA), KLKs are found to be PRESTWICK SPECTRUM 80 LOPAC 60 implicated in cancer-related processes including invasion, metastasis and angiogenesis. Therefore, 60 70 50 ROBOT modulators of expression of KLKs might help us understand their regulatory pathways and be of 50 60 2X SD 2X SD 50 40 40 40 DMSO therapeutic value. s 30 30 DMSO 2x SD KLK5 (ug/ L) 30 20 20 2X SD DMSO A cell-based high throughput screening of 3 compound libraries (~4000 small molecules) was 2X SD 20 KLK5 (ug/L) KLK5 10 performed under fully automated robotic facilities and sensitive immunoassays (ELISA) were used to 10 10 2x SD 0 0 0 (ug/L) KLK5 levels expression 0 200 400 600 800 1000 1200 1400 0 200 400 600 800 1000 1200 measure KLKs in a panel of different cell lines. The ‘validated leads’ were further assayed in-vitro, to compounds 0 500 1000 1500 2000 2500 measure their effectiveness (IC50s) at protein (ELISA) and mRNA levels (RT-PCR), cytotoxicity (LDH) compounds compounds and cell viability (MTT assay). Fig.1. Initial Screening of the 3 libraries ( ~4000 compounds) identified 66 small molecules as The initial screening resulted in 66 ‘putative hits’ that decreased KLK expression by at least 50% over putative hits. -
United States Patent (10) Patent No.: US 8,758,723 B2 Yang Et Al
US008758723B2 (12) United States Patent (10) Patent No.: US 8,758,723 B2 Yang et al. (45) Date of Patent: Jun. 24, 2014 (54) COMPOSITIONS AND METHODS FOR 5,164,294 A 11/1992 Skold et al. .................... 435/7.5 CELLULAR MAGING AND THERAPY 5,242,679 A 9/1993 Fritzberg et al. 424/1.53 5,268,163 A 12/1993 Verbruggen ...... ... 534f14 5,279,811 A 1/1994 Bergstein etal 424/1.65 (75) Inventors: David J. Yang, Sugar Land, TX (US); 5,310,536 A 5/1994 Srinivasan .... 424/1.65 Chang-Sok Oh, Houston, TX (US); 5,356,793 A 10/1994 Koezuka et al. ... 435/32 Dong-Fang Yu, Houston, TX (US); Ali 5,364,613 A 1 1/1994 Sieving et al. ... ... 424/9.3 Azhdarinia, Houston, TX (US); Saady 5,412,072 A 5/1995 Sakurai et al. 530,322 ... s s 5,416,016 A 5/1995 Low et al. ..... 435/375 Kohanim, Sugar Land, TX (US) 5,474,756 A 12/1995 Tweedle et al. 424,9363 5,517,993 A 5/1996 Unger et al. .. ... 600,410 (73) Assignee: The Board of Regents of the University 5,534.241 A 7/1996 Torchilin et al. 424/9.321 of Texas System, Austin, TX (US) 5,541,287 A 7, 1996 Yau et al. ...................... 530.317 5,601,800 A 2f1997 Katti et al. 424,177 (*) Notice: Subject to any disclaimer, the term of this 5,605,671 A 2/1997 Lyle et al. ... 424/1.41 patent is extended or adjusted under 35 5,605,672 A 2/1997 Bogdanov et al. -
Search Strategy: Database: Ovid MEDLINE(R) 1946 to Present with Daily Update ------1 Exp Ventricular Dysfunction, Right/ 2 (Right.Ab,Ti,Sh
Search Strategy: Database: Ovid MEDLINE(R) 1946 to Present with Daily Update -------------------------------------------------------------------------------- 1 exp Ventricular Dysfunction, Right/ 2 (Right.ab,ti,sh. and ((cardiac* or ventri* or myocardi* or heart* or chamber*) adj3 (fail* or output* or out-put* or function* or insufficien* or systol* or pump* or dys-function* or dysfunction*)).mp.) or (cor adj pulmonal*).ti,ab,sh. 3 cardiotonic*.ti,ab,sh. or exp Cardiotonic Agents/ 4 exp cardenolides/ or exp digitoxin/ or exp acetyldigitoxins/ or exp digitoxigenin/ or exp digoxin/ or exp acetyldigoxins/ or exp digoxigenin/ or exp medigoxin/ or exp strophanthins/ or exp cymarine/ or exp ouabain/ or exp strophanthidin/ or exp cardiac glycosides/ or exp bufanolides/ or exp digitalis glycosides/ or exp lanatosides/ or exp deslanoside/ 5 (cardinolide* or digitox* or acetyldig* or digoxin* or medigox* or strophanthidin* or cymarin* or ouabain* or strophanthidin* or (cardiac* adj glycoside*) or bufanolide* or lanatoside* or deslanosid*).mp. 6 (1 or 2) and (3 or 4 or 5) *************************** Embase.com #1. 'right ventricular failure'/exp #2. right AND (cardiac* OR ventri* OR myocardi* OR heart* OR chamber*) NEAR/3 (fail* OR output* OR function* OR insufficien* OR systol* OR pump* OR dysfunction*) OR cor NEXT/1 pulmonal* #3. cardiotonic* #4. 'cardenolides'/exp OR 'cardenolides' OR 'digitoxin'/exp OR 'digitoxin' OR 'acetyldigitoxins'/exp OR 'acetyldigitoxins' OR 'digitoxigenin'/exp OR 'digitoxigenin' OR 'digoxin'/exp OR 'digoxin' OR 'acetyldigoxins'/exp OR 'acetyldigoxins' OR 'digoxigenin'/exp OR 'digoxigenin' OR 'medigoxin'/exp OR 'medigoxin' OR 'strophanthins'/exp OR 'strophanthins' OR 'cymarine'/exp OR 'cymarine' OR 'ouabain'/exp OR 'ouabain' OR 'strophanthidin'/exp OR 'strophanthidin' OR 'cardiac glycosides'/exp OR 'cardiac glycosides' OR 'bufanolides'/exp OR 'bufanolides' OR 'digitalis glycosides'/exp OR 'digitalis glycosides' OR 'lanatosides'/exp OR 'lanatosides' OR 'deslanoside'/exp OR 'deslanoside' #5.